This is reflected in the fact that although ART coverage has increased substantially over the last decade, the average CD4 cell count at the start of treatment has only increased modestly [10,11]; many people still only start ART when they are at an advanced stage of immunosuppression, implying many years between infection and initiation of ART. This evidence concerns the gene CD4 and infection.